Cannell Capital LLC Acquires New Shares in OraSure Technologies, Inc. $OSUR

Cannell Capital LLC acquired a new position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,427,419 shares of the medical instruments supplier’s stock, valued at approximately $6,366,289. OraSure Technologies comprises approximately 0.0% of Cannell Capital LLC’s portfolio, making the stock its 9th largest holding.

Other institutional investors and hedge funds have also bought and sold shares of the company. Quadrature Capital Ltd bought a new position in OraSure Technologies in the fourth quarter valued at about $28,000. Legal & General Group Plc bought a new stake in shares of OraSure Technologies during the second quarter worth about $30,000. Prudential Financial Inc. bought a new stake in shares of OraSure Technologies during the second quarter worth about $31,000. Diversify Wealth Management LLC acquired a new position in shares of OraSure Technologies in the first quarter valued at approximately $36,000. Finally, Diversify Advisory Services LLC acquired a new position in shares of OraSure Technologies in the second quarter valued at approximately $47,000. Institutional investors and hedge funds own 93.50% of the company’s stock.

Get OraSure Technologies alerts:

OraSure Technologies Stock Down 2.4%

Shares of NASDAQ:OSUR opened at $3.60 on Friday. The firm has a market cap of $248.29 million, a P/E ratio of -5.22 and a beta of 1.00. OraSure Technologies, Inc. has a 12-month low of $2.08 and a 12-month high of $4.58. The business has a fifty day simple moving average of $4.05 and a 200 day simple moving average of $3.54.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on OSUR shares. Wall Street Zen upgraded shares of OraSure Technologies from a “sell” rating to a “hold” rating in a report on Monday, August 10th. Weiss Ratings raised shares of OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $3.00.

Get Our Latest Analysis on OraSure Technologies

OraSure Technologies Profile

(Free Report)

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.

Recommended Stories

• Five stocks we like better than OraSure Technologies
• 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
• IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
• Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
• Okta Stock Surges 29%—Is $200 the Next Stop?

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR – Free Report).

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.